Evidence map›Paper›PMID 40956622›Full record

ArticleJCI insight2025

Abrogation of FGFR signaling blocks β-catenin-induced adrenocortical hyperplasia and aldosterone production.

Vasileios Chortis, Dulanjalee Kariyawasam, Mesut Berber, Nick A Guagliardo, Sining Leng, Betul Haykir, Claudio Ribeiro, Manasvi S Shah, Emanuele Pignatti, Brenna Jorgensen and 5 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vasileios ChortisDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Dulanjalee KariyawasamDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Mesut BerberDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Nick A GuagliardoDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
Sining LengDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Betul HaykirDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Claudio RibeiroDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Manasvi S ShahDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Emanuele PignattiDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Brenna JorgensenDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Lindsey GastonDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Paula Q BarrettDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
Diana L CarloneDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
Kleiton Silva BorgesDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.
David T BreaultDivision of Endocrinology, Boston Children's Hospital, Boston, Massachusetts, USA.

Funding

Rosettes in Adrenal Development, Maintenance and DiseaseR01DK123694 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI David T Breault · 2019 to 2026
$5.6M
NIDDK NIH HHS R01 DK123694
6 · The paper itself

Abstract

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors critical for organogenesis and tissue maintenance, including in the adrenal gland. Here we delineate the role of FGFR2 in the morphogenesis, maintenance, and function of the adrenal cortex with a focus on the zona glomerulosa (zG). zG-specific Fgfr2 deletion (Fgfr2-cKO) resulted in impaired zG cell identity, proliferation, and transdifferentiation into zona fasciculata (zF) cells during postnatal development. In adult mice, induced deletion of Fgfr2 led to loss of mature zG cell identity, highlighting the importance of FGFR2 for the maintenance of a differentiated zG state. Strikingly, Fgfr2-cKO was sufficient to fully abrogate β-catenin-induced zG hyperplasia and to reduce aldosterone levels. Finally, short-term treatment with pan-FGFR small molecule inhibitors suppressed aldosterone production in both WT and β-catenin gain-of-function mice. These results demonstrate a critical role for FGFR signaling in adrenal morphogenesis, maintenance, and function and suggest that targeting FGFR signaling may benefit patients with aldosterone excess and/or adrenal hyperplasia.

Indexed as

Adrenal CortexAldosteronebeta CateninReceptor, Fibroblast Growth Factor, Type 2AnimalsFemaleHyperplasiaMaleMiceMice, KnockoutSignal TransductionZona GlomerulosaAldosteronebeta CateninCTNNB1 protein, mouseFgfr2 protein, mouseReceptor, Fibroblast Growth Factor, Type 2CardiologyEndocrinologyHomeostasisHypertensionMouse models

Identifiers

PMID40956622
PMCPMC12643481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.